Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide

Clinical Cancer Research

Volumn 6, Issue 11, 2000, Pages 4343-4350

  Bianco, Cataldo ^a,b   Bianco, Roberto ^a   Tortora, Giampaolo ^a   Damiano, Vincenzo ^a   Guerrieri, Patrizia ^b   Montemaggi, Paolo ^b   Mendelsohn, John ^c   De Placido, Sabino ^a   Bianco, A Raffaele ^a   Ciardiello, Fortunato ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Azienda Ospedaliera Annunziata di Cosenza   (Italy)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CETUXIMAB; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GENE EXPRESSION MODULATOR 231;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; COLON CANCER; FEMALE; HUMAN; HUMAN CELL; IONIZING RADIATION; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; CYCLIC AMP-DEPENDENT PROTEIN KINASES; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0033748391     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation
2. Radiation-induced release of transforming growth factor α activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death
3. Epidermal growth factor-related peptides and their receptors in human malignancies
4. A multidrug resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo
5. Altered gene expression in drug-resistant human breast cancer cells
6. Therapeutic application of anti-growth factor receptor antibodies
7. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain
8. Epidermal growth factor receptors in human breast carcinoma cells: A potential selective target for transforming growth factor α-Pseudomonas exotoxin 40 fusion protein
9. Selective toxicity of TGF-α-PE40 to EGFR-positive cell lines: Selective protection of low EGFR-expressing cell lines by EGF
10. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors
11. Targeted inhibition of tumor cell growth by a bispecific single-chain toxin containing an antibody domain and TGFα
12. 4,5-Bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity
13. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies
14. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice
15. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction
16. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
17. A study of anti-epidermal growth factor receptor (EGFr) monoclonal antibody C225 and cisplatin in patients (pts) with head and neck or lung carcinomas
18. Dose dependent pharmacokinetics of a chimerized monoclonal antibody (C225) against EGFR
19. Phase I study of anti-epidermal growth factor receptor antibody C225 in combination with irradiation in patients with advanced squamous cell carcinoma of the head and neck
20. The regulatory subunit of cAMP-dependent protein kinase as a target for chemotherapy of cancer and other cellular dysfunctional-related diseases
21. Interactions between the epidermal growth factor receptor and type I protein kinase A: Biological significance and therapeutic implications
22. The RIα subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor
23. An antisense oligodeoxynucleotide that depletes RIα subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells
24. A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth
25. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A
26. In vivo studies with antisense oligonucleotides
27. Antisense therapeutics
28. A safety and pharmacokinetic study of mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hours infusions in patients with refractory solid tumors
29. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
30. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
31. Antitumor activity of sequential treatment with topotecan and antiepidermal growth factor receptor monoclonal antibody C225
32. Cooperative antiproliferative effects of 8-Cl-cAMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells
33. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A
34. Cooperative inhibition of renal cancer growth by anti-EGF receptor antibody and protein kinase A antisense oligonucleotide
35. Epidermal growth factor receptor family and chemosensitization
36. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
37. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
38. Continued response following treatment with IMC-C225, an EGFr MoAb, combined with RT in advancer head and neck malignancies